Strategic Investments

Strategic Investments Overview

OPKO’s growth strategy includes investing in early-stage companies that we perceive to have valuable proprietary technology and significant potential to create value for OPKO as a shareholder. Some of our investments include:

ARNO Therapeutics

ARNO Therapeutics (Flemington, NJ), a publicly traded biopharmaceutical company focused on the clinical development of targeted cancer therapies and novel drug candidates for unmet medical needs.  ARNO has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates.  These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors. More »


BioCardia Inc. is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. They are developing two comprehensive biotherapeutic candidates, CardiAMP™, an autologous minimally processed bone marrow cells, for heart failure and post-acute infraction; and CardiALLO™, allogenic cultured expanded mesenchymal stem cells derived from bone marrow, also for heart failure and post-acute infraction. These programs are enabled by the Company’s Helix™ transendocrardial systems and Morph® vascular access products. More »

ChromaDex Corporation

ChromaDex Corporation (Irvine, CA), a publicly traded entity, is a leading provider of proprietary ingredients and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical, and cosmetic markets. In 2011, ChromaDex launched BluScience™, a line of dietary supplements based on pterostilbene, an antioxidant compound found in blueberries. This product line is currently marketed nationwide through GNC and Walgreens. In addition to stock investments in Chromadex, OPKO also holds distribution rights to certain ChromaDex products in Latin America. More »

Cocrystal Pharma

Cocrystal Pharma (Bothell, WA), a publicly traded biopharmaceutical company focused on the discovery and development of novel small molecule antiviral therapeutics tailored for the treatment of serious and chronic viral diseases, It is currently developing oral, small molecule, antiviral therapeutics for Hepatitis C and influenza. More »


MABVAX (San Diego, CA) Mabvax Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative vaccine and monoclonal antibody-based therapeutics for the diagnosis and treatment of cancer. More »


Neovasc, Inc. (Vancouver BC, Canada), a publicly-traded company named the 2012 Medical Device Company of the Year by LifeSciences British Columbia. Featuring a line of products that are approved for sale and distribution worldwide, Neovasc develops, manufactures, and markets innovative vascular devices such as the Neovasc Reducer™ for refractory angina and PeriPatch™ surgical tissue used in cardiac reconstruction. More »


Pharmsynthez (St. Petersberg, Russia), a publicly traded pharmaceutical company that manufactures and markets medicines used in oncology, gynecology, viral diseases and tuberculosis, and conducts clinical development of therapeutic vaccines and bio superiors. More »

RXi Pharmaceuticals

RXi Pharmaceuticals (Marlborough, MA), a publicly traded biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform.  Therapeutics that use RNA interference, or “RNAi,” have great promise because of their ability to “silence,” or down-regulate, the expression of a specific gene that may be overexpressed in a disease condition.  Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXi’s first RNAi product candidate, RXI-109, entered into RXi’s first human clinical trial in 2012.  RXI-109 targets connective tissue growth factor (CTGF), a key regulator of fibrosis and scar formation, and is initially being developed to reduce or inhibit scar formation in the skin following surgery. More »

VBI Vaccines

VBI Vaccines Inc. ( Nasdaq: VBIV ) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI’s first marketed product is Sci-B-Vac™, a hepatitis B (“HBV”) vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vacis approved for use in Israel and 14 other countries. VBI’s eVLP Platform technology allows for the development of enveloped (“e”) virus-like particle (“VLP”) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus (“CMV”) and glioblastoma multiforme (“GBM”). VBI is also advancing its LPV™ Thermostability Platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel. More »


Sevion (Bridgewater, NJ) acquired Fabrus (San Diego, CA) in May 2014 and is a publicly traded clinical-stage biotech company specializing in cancer therapeutics. Its proprietary gene regulation technology has demonstrated the ability to kill cancer cells and protect healthy cells from premature death in disease models.  Fabrus is an early stage biotechnology company with next generation therapeutic antibody drug discovery and development capabilities that is using its proprietary antibody screening and engineering approach to discover promising lead compounds against several important oncology targets. More »

Xenetic Biosciences

Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics. Their proprietary drug development platforms include PolYXen, which enables biological drugs by improving their half-life. Xenetics lead investigational product candidates include FDA orphan designated oncology therapeutic XBIO-101 for the treatment of progesterone receptor negative endometrial cancer and a polysialyated form of erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease. Xenetic also is developing, in partnership with Shire plc, a product SHP656 (PSA Factor VII) for Hemophilia A. More »

Zebra Biologics

Zebra Biologics, Inc. (San Diego, CA), a privately held biotechnology company focused on the discovery and development of biosuperior antibody therapeutics and complex drug targets. Zebra’s patented platform is an advanced version of a core technology that underlies the discovery and commercial success of AbbVie Inc.’s Humira™, developed by Richard Lerner, M.D., at The Scripps Research Institute. The technology allows for the selection of antibodies for function rather than through simple binding. Zebra has already developed an early pre-clinical pipeline of candidate antibodies with significant commercial potential in regulating diabetes and obesity, cancer, and treatment of neurological disease. More »